Q5160 Bevacizumab-nwgd (Jobevne) - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Bevacizumab-nwgd (Jobevne)

Brand Name:

Jobevne

Strength:

10mg

HCPCS:

Q5160

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

VEGFR

Oral (Y/N):

No

FDA Approval Year:

2025

FDA Discontinuation Year:

CMS Effective Date:

Jan. 1, 2026

CMS Discontinuation Date:

Status:

In Use